Navigation Links
Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
Date:3/3/2017

CONCORD, Mass., March 3, 2017 /PRNewswire/ -- Valerion Therapeutics announced today that it has developed a fusion protein, VAL-1221, which combines its proprietary antibody delivery technology with recombinant human acid alpha-glucosidase (rhGAA) to improve the delivery of rhGAA into affected tissues of patients with Pompe disease (Glycogen Storage Disease, Type II; GSDII).  Pompe disease is caused by a deficiency of the lysosomal enzyme, GAA, that leads to accumulation of glycogen in multiple tissues, with cardiac and skeletal muscles being the most severely affected.  Glycogen, a complex sugar, is known to accumulate in both the lysosomes and cytoplasm of late-onset Pompe disease patients. However, the currently approved enzyme-replacement therapy is limited to the lysosome for therapeutic activity.

In a study recently published by Sun et al, Duke University, Division of Medical Genetics (J Mol Med, 2 Feb, 2017), Valerion's proprietary antibody-mediated enzyme replacement therapy [VAL-1221 (humanized 3E10Fab-GAA)] demonstrated efficacy in both cultured Pompe patient fibroblasts and in Pompe (GAA-deficient) mice. Importantly, not only did VAL-1221 reduce lysosomal glycogen accumulation as effectively as rhGAA (current enzyme replacement therapy or ERT) but it was also demonstrated to penetrate living cells independent of the mannose-6-phopsphate receptor (M6PR), the mechanism of cell entry associated with current ERT which directs enzyme to the lysosome. These results suggest that VAL-1221 has potential benefit over current ERT by clearing both lysosomal and cytoplasmic glycogen.  

Valerion is initiating a clinical trial in both the US (Duke University Medical Center) and the UK (The National Hospital for Neurology and Neurosurgery, London) next month to evaluate this novel therapy in patients with late-onset Pompe disease.

"We believe our findings are a game-changer in the treatment of Pompe disease," said Deborah Ramsdell, Valerion's Chief Executive Officer. "We are excited about the potential to help patients who are looking for alternatives to the current approved therapy."

This randomized, parallel active control, single and repeat dose, dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of VAL-1221 in ambulatory and ventilator-free patients with late-onset Pompe Disease.  Top line results are expected later this year.

"The approach is different from other ERT approaches as this has the ability to act on glycogen in the cytoplasm. This remains a challenge in the field of Pompe disease," said Dr. Priya Kishnani, Principal Investigator at Duke University Medical Center. "Glycogen that is leached out (either due to shearing effect or rupture of lysosomes) into cytoplasm needs to be cleared.  The collaboration with Valerion is an important one as it allows us to look at whether VAL-1221 has this additional benefit."

About Valerion Therapeutics

Valerion Therapeutics (www.valerion.com) is a biotechnology company focused on developing therapies for orphan genetic diseases utilizing a proprietary antibody-mediated delivery platform to target specific tissues. 

This platform is capable of enhanced intracellular delivery of a variety of active therapeutic molecules via a well-known and broadly studied transport mechanism that is present in muscles and neurons.  Pipeline candidates include therapies aimed at addressing orphan genetic disorders with limited or no current therapies.  Valerion Therapeutics is part of the Alopexx Enterprises portfolio of companies (www.alopexx.com).

Media Contact  
Deborah Ramsdell  
Deb.ramsdell@alopexx.com  
781-775-7688

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valerion-therapeutics-demonstrates-a-new-mechanism-for-treating-pompe-disease-300417564.html


'/>"/>
SOURCE Valerion Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. How These Biotech Stocks are Faring? -- Geron, Incyte, Illumina, and Bellerophon Therapeutics
2. Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting
3. Global Breast Cancer Therapeutics Market Analysis 2016-2022: Company Profiling Covering the Financials, Recent Activities and Future Strategies - Research and Markets
4. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Strategic Business Report 2017-2022 - Research and Markets
5. United Therapeutics Corporation To Present At Cowen And Company 37th Annual Health Care Conference
6. MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer
7. Dermatology Therapeutics Drug Development Pipeline Review, 2016: Approximately One-Third of the US Population Suffers from at Least One Active Skin Condition - Research and Markets
8. Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference Call And Webcast
9. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pharmaceuticals
10. Global Peripheral Arterial Disease (PAD) Therapeutics - Pharmaceuticals
11. Entest BioMedical Inc.s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017 West Pharmaceutical Services, Inc. ... for injectable drug administration, today announced that it will ... on Thursday, October 26, 2017, and will follow with ... expectations at 9:00 a.m. Eastern Time. To participate on ... The conference ID is 94093362. ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):